Monopar Therapeutics (NASDAQ:MNPR) Raised to “Hold” at Wall Street Zen

Monopar Therapeutics (NASDAQ:MNPR) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other brokerages also recently commented on MNPR. Piper Sandler set a $105.00 target price on shares of Monopar Therapeutics in a report on Tuesday, June 2nd. UBS Group set a $125.00 price target on shares of Monopar Therapeutics in a report on Thursday, July 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, July 15th. BTIG Research increased their price objective on shares of Monopar Therapeutics from $104.00 to $117.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $112.08.

Monopar Therapeutics Stock Performance

Shares of Monopar Therapeutics stock opened at $119.21 on Friday. The company has a market capitalization of $798.71 million, a P/E ratio of -62.74 and a beta of 1.47. The stock has a fifty day simple moving average of $90.83 and a 200 day simple moving average of $70.05. Monopar Therapeutics has a 12-month low of $29.18 and a 12-month high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.41. On average, analysts predict that Monopar Therapeutics will post -2.82 EPS for the current year.

Institutional Trading of Monopar Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. bought a new position in shares of Monopar Therapeutics during the 3rd quarter valued at approximately $28,000. BNP Paribas Financial Markets raised its holdings in shares of Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after purchasing an additional 349 shares during the period. Sei Investments Co. raised its holdings in shares of Monopar Therapeutics by 9.5% in the 1st quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock worth $415,000 after purchasing an additional 656 shares during the period. Meeder Asset Management Inc. purchased a new position in Monopar Therapeutics in the fourth quarter valued at approximately $65,000. Finally, Caitong International Asset Management Co. Ltd purchased a new position in Monopar Therapeutics in the fourth quarter valued at approximately $86,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.